MEDANTA - Global Health

📊 NSE: MEDANTA 🏢 Healthcare 📅 Last Updated: 12/13/2025 22:23

💰 Financial Performance

Revenue Growth by Segment

Matured hospitals (Gurugram, Indore, Ranchi) grew 10.6% YoY to INR 26,119 million in FY25; Developing hospitals (Lucknow, Patna) grew 10% YoY to INR 10,940 million. Outpatient pharmacy revenue increased 26% from INR 1,120 million to INR 1,400 million. International patient revenue grew 7.8% in FY25 and surged 49% YoY in Q2 FY26 to INR 762 million.

Geographic Revenue Split

Revenue is diversified across 5 states. Matured facilities (Gurugram, Indore, Ranchi) contribute approximately 70.5% of healthcare services revenue, while developing facilities (Lucknow, Patna) contribute 29.5%. International patients account for approximately 5.5% of total revenue in FY25.

Profitability Margins

Consolidated PAT margin was 12.8% in FY25. In Q2 FY26, PAT margin improved to 14.2% from 13.4% YoY. Standalone profitability declined 5.1% due to one-time merger provisioning, while consolidated PAT grew 0.68% in FY25 to INR 4,813.18 million.

EBITDA Margin

Consolidated EBITDA margin was 25.4% in FY25 (INR 9,561.6 million), down from 26.1% YoY. Q2 FY26 EBITDA margin (ex-Noida) was 25.2%, while including Noida startup losses, the margin was 23.3% (INR 2,607 million).

Capital Expenditure

H1 FY26 capex was INR 4,252 million. Total planned project capex is estimated at INR 36,700 million for 2,000 additional beds. Maintenance capex is projected at INR 4,500 million over the next three years. The Noida project cost was revised upward to INR 15,300 million to accommodate 750 beds.

Credit Rating & Borrowing

CRISIL A+/Positive rating for major subsidiaries. Interest coverage ratio improved to 10.5 times in fiscal 2024 from 7.83 times. Debt-to-Equity ratio improved to 0.10x in FY25 from 0.14x following debt repayment.

⚙️ Operational Drivers

Raw Materials

Medical consumables, pharmaceuticals, and surgical implants represent the primary variable costs, though specific % of total cost is not disclosed. Employee benefits (doctors/nurses) are a major cost driver with 11,800+ staff.

Import Sources

Not specifically disclosed, but medical equipment like the 128-slice Dual Source CT and MAGNETOM Altea 1.5 Tesla MRI are sourced from global medical technology providers.

Key Suppliers

Partnerships include US-based firms for DOCBOX cardiac monitoring and Qure.ai for AI-powered imaging decision support.

Capacity Expansion

Current capacity includes 57 new beds added at Patna in H1 FY26. Planned expansion of 1,000 beds across Noida, Lucknow, Patna, and Ranchi, plus 2,000 beds via greenfield projects in Mumbai (Oshiwara), Pitampura (Delhi), and Guwahati (Assam) over 3-4 years.

Raw Material Costs

Inventory turnover improved to 13.13x in FY25 from 11.94x, indicating more efficient management of medical supplies and pharmacy stock.

Manufacturing Efficiency

Occupancy stood at ~64% in Q2 FY26 on increased bed capacity. ARPOB (Average Revenue Per Occupied Bed) grew 5.5% YoY to INR 65,570, reflecting better case mix and realization.

Logistics & Distribution

Not disclosed as a % of revenue; however, the company operates hospital-based and retail outpatient pharmacies which grew 26% in revenue.

📈 Strategic Growth

Expected Growth Rate

15%

Growth Strategy

Growth will be driven by adding 2,000 beds through greenfield projects in Mumbai, Delhi, and Guwahati, and scaling the 750-bed Noida facility. The company is also increasing its international patient reach (49% growth in Q2 FY26) and expanding its outpatient pharmacy and digital health (AI/predictive analytics) offerings.

Products & Services

Tertiary and quaternary healthcare services specializing in Cardiac Sciences, Oncology, Gastroenterology, Neurosciences, and Renal Sciences/Urology, which contribute 65.8% of revenue.

Brand Portfolio

Medanta, Global Health Limited, Medanta The Medicity.

New Products/Services

Launch of Medanta Noida in September 2025 (INR 39 million revenue in month one). New AI-powered services like DOCBOX and Qure.ai imaging support are expected to enhance clinical outcomes.

Market Expansion

Expansion into Mumbai (Oshiwara), Pitampura (Delhi), and Guwahati (Assam) with large-format greenfield hospitals over the next 3-4 years.

Market Share & Ranking

Not specifically ranked by %, but described as a 'trusted leader' and 'destination for high-end tertiary care' in North and East India.

Strategic Alliances

Collaborations with the UP state government for 'Mission TB-Free' and partnerships with US-based firms for cardiac critical care monitoring systems.

🌍 External Factors

Industry Trends

The industry is shifting toward digital health and AI integration. Medanta is positioning itself by adopting AI-powered imaging and next-gen cardiac monitoring to maintain its 'destination care' status.

Competitive Landscape

Faces competition from other private hospital chains in metro areas, which risks talent poaching and pressure on occupancy rates.

Competitive Moat

Moat is built on 'Clinical Excellence' and a 'Doctor-led' model. The brand reputation for complex quaternary care (65.8% revenue from top 5 specialties) and high-end infrastructure makes it difficult for new entrants to replicate.

Macro Economic Sensitivity

Highly sensitive to healthcare spending trends and insurance penetration. Growing demand for high-quality healthcare in underserved regions like Patna and Lucknow drives the 10% growth in developing hospitals.

Consumer Behavior

Shift toward seeking 'destination care' for complex surgeries, benefiting Medanta's high-end tertiary model.

Geopolitical Risks

Medical value travel (international patients) is subject to geopolitical stability and visa regulations, impacting the 5.5% revenue share from this segment.

⚖️ Regulatory & Governance

Industry Regulations

Compliance with the Companies Act 2013, SEBI Listing Regulations, and healthcare-specific standards for clinical excellence and patient safety.

Environmental Compliance

ESG oversight is managed by the Board; initiatives include the 'TB-Free Uttar Pradesh' campaign and early breast cancer detection programs.

Taxation Policy Impact

Effective tax rate resulted in tax expenses of INR 1,659.39 million on PBT of INR 6,472.57 million (approx 25.6%) in FY25.

Legal Contingencies

The company monitors brand equity risks related to legal non-compliance or patient dissatisfaction; specific pending case values are not disclosed in the provided text.

⚠️ Risk Analysis

Key Uncertainties

Expansion risk: Delays in constructing the 2,000-bed pipeline could impact projected returns. People risk: High turnover of skilled professionals could damage brand reputation.